Kodiak Sciences (NASDAQ:KOD) Price Target Raised to $96.00

Kodiak Sciences (NASDAQ:KOD) had its price target upped by HC Wainwright from $58.00 to $96.00 in a report released on Monday, Marketbeat Ratings reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Kodiak Sciences’ FY2027 earnings at ($3.36) EPS, FY2028 earnings at ($1.78) EPS, FY2029 earnings at $1.76 EPS and FY2030 earnings at $5.81 EPS.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kodiak Sciences in a report on Friday, July 10th. JPMorgan Chase & Co. raised their price target on shares of Kodiak Sciences from $56.00 to $66.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. The Goldman Sachs Group assumed coverage on shares of Kodiak Sciences in a research report on Thursday, September 24th. They set a “neutral” rating and a $36.00 price target on the stock. Finally, Wall Street Zen cut shares of Kodiak Sciences from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 26th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $100.43.

Kodiak Sciences Price Performance

Shares of Kodiak Sciences stock opened at $94.80 on Monday. The business has a 50 day simple moving average of $41.32 and a two-hundred day simple moving average of $38.77. The stock has a market capitalization of $5.96 billion, a P/E ratio of -22.63 and a beta of 2.18. Kodiak Sciences has a 12 month low of $10.94 and a 12 month high of $98.80.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.09). As a group, research analysts anticipate that Kodiak Sciences will post -3.89 EPS for the current fiscal year.

Insider Transactions at Kodiak Sciences

In related news, Director Bros. Advisors Lp Baker bought 33,726 shares of the business’s stock in a transaction on Tuesday, September 29th. The stock was acquired at an average cost of $85.05 per share, with a total value of $2,868,396.30. Following the purchase, the director directly owned 20,191,214 shares of the company’s stock, valued at $1,717,262,750.70. The trade was a 0.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last three months, insiders acquired 1,941,755 shares of company stock valued at $156,986,026. 44.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Kodiak Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Engineers Gate Manager LP boosted its position in shares of Kodiak Sciences by 145.8% during the 2nd quarter. Engineers Gate Manager LP now owns 29,537 shares of the company’s stock worth $1,151,000 after purchasing an additional 17,520 shares during the period. Squarepoint Ops LLC lifted its stake in Kodiak Sciences by 112.6% during the second quarter. Squarepoint Ops LLC now owns 151,098 shares of the company’s stock worth $5,887,000 after purchasing an additional 80,042 shares in the last quarter. Arizona State Retirement System boosted its position in shares of Kodiak Sciences by 6.9% during the second quarter. Arizona State Retirement System now owns 8,533 shares of the company’s stock worth $332,000 after buying an additional 554 shares during the period. Hsbc Holdings PLC purchased a new position in shares of Kodiak Sciences during the second quarter worth $232,000. Finally, Wellington Management Group LLP grew its stake in shares of Kodiak Sciences by 81.9% in the second quarter. Wellington Management Group LLP now owns 793,613 shares of the company’s stock valued at $30,919,000 after buying an additional 357,284 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Strong Phase 3 results drive investor enthusiasm. Zenkuda and KSI-501 reportedly achieved their primary goals in the DAYBREAK study for wet age-related macular degeneration, meeting key endpoints against Eylea. Kodiak is advancing Zenkuda toward a biologics license application (BLA), creating a potential path toward regulatory review in a large retinal-drug market. Zenkuda positive wet AMD data article
• Positive Sentiment: HC Wainwright raised its long-term earnings outlook. The firm lifted its FY2029 EPS forecast to $1.76 from $0.18 and its FY2030 forecast to $5.81 from $3.04. It maintained a Buy rating and a $96 price target, while projecting a transition from losses in FY2027 and FY2028 to profitability in FY2029. Kodiak Sciences analyst estimates
• Positive Sentiment: Insider purchases provide a confidence signal. Director Bros. Advisors LP Baker reported multiple purchases totaling roughly 1.94 million shares for approximately $157 million across September 28–29. The buying materially increased the director’s already substantial ownership stake. SEC insider ownership filing
• Neutral Sentiment: Near-term analyst revisions were mixed. HC Wainwright slightly reduced its FY2027 loss estimate to $3.36 per share from $3.27, but improved forecasts for later years as it incorporated the potential impact of Zenkuda.
• Negative Sentiment: Investors face substantial execution and financing risks. Kodiak has no current revenue and continues to burn cash, making a future share offering possible. Unusually high put-option buying also suggests some traders are positioning for volatility or a pullback after the dramatic rally. Kodiak valuation and financing risks article

Kodiak Sciences Company Profile

Kodiak Sciences Inc (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.